Method to prepare hirsutella sinensis polysaccharides possessing anti-obesity properties and uses thereof
09782431 · 2017-10-10
Assignee
Inventors
- Yun-Fei Ko (Taipei, TW)
- Jan Martel (Taipei, TW)
- Jian-Ching Liau (Taipei, TW)
- I-Te Chang (Taipei, TW)
- Chien-Sheng Lee (Taipei, TW)
- Wei-Chang Wang (Taipei, TW)
- Chen-Yaw Chiu (Taipei, TW)
- Chih-Jung Chang (Taipei, TW)
- Chuan-Sheng Lin (Taipei, TW)
- Tsung-Ru Wu (Taipei, TW)
- Chia-Chen Lu (Taipei, TW)
- David Marcelo Ojcius (Taipei, TW)
- Hsin-Chih Lai (Taipei, TW)
- Ding-E Young (Taipei, TW)
Cpc classification
A61K31/736
HUMAN NECESSITIES
C08B37/0003
CHEMISTRY; METALLURGY
A61K45/06
HUMAN NECESSITIES
C08B37/0087
CHEMISTRY; METALLURGY
International classification
A61K31/736
HUMAN NECESSITIES
C08B37/00
CHEMISTRY; METALLURGY
Abstract
The present invention provides a method to prepare polysaccharides from Hirsutella sinensis. The prepared polysaccharides reduce body weight and fat accumulation in laboratory animals, and can therefore be used to prevent and treat obesity.
Claims
1. A method for treating obesity, comprising administering an effective amount of a polysaccharide extracted from Hirsutella sinensis to a subject in need thereof, wherein the polysaccharide is isolated from a water extract of H. sinensis mycelium and contains at least mannose, glucose, and galactose; wherein treating obesity consists of reducing body weight, body weight gain and fat accumulation.
2. The method according to claim 1, wherein the polysaccharide further contains fucose, rhamnose, arabinose, glucosamine, and galactosamine.
3. The method according to claim 2, wherein a weight ratio of the fucose, rhamnose, arabinose, glucosamine, galactose, glucose, mannose, and galactosamine in the polysaccharide ranges from 3:3:1:4:23:12:50:0.2 to 4:4:2:5:24:13:51:0.6.
4. The method according to claim 1, wherein the effective amount of the polysaccharide given to the subject ranges from 0.001 mg/kg to 1 g/kg.
5. The method according to claim 1, wherein the polysaccharide has a molecular weight ranging from 15,776 Da to 1,231,969 Da, and a polydispersity index (Mw/Mn) of 7.475.
6. The method according to claim 1, wherein an average molecular weight of the polysaccharide is 312 kDa.
7. The method according to claim 1, wherein the effective amount of the polysaccharide is 0.0646 g per kilogram of body weight.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The following drawings form part of the present specification and are included here to further demonstrate some aspects of the present invention, which can be better understood by reference to one or more of these drawings, in combination with the detailed description of the embodiments presented herein:
(2)
(3)
(4)
(5)
(6)
(7)
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
(8) In the following description of the embodiments of the present invention, reference is made to the accompanying drawings, which are shown to demonstrate the specific embodiments in which the present disclosure may be practiced. These embodiments are provided to enable those skilled in the art to practice the present disclosure, and it is understood that changes can be made to the embodiments without departing from the scope of the present invention. The following description is therefore not to be considered as limiting the scope of the present invention.
Definition
(9) The “effective dosage” or “effective amount” described in the present invention refers to the amount of H. sinensis polysaccharide that can reduce body weight and fat accumulation in animals and humans. The appropriate effective dosage may vary depending on the organism or individual treated but can be determined experimentally using various techniques, including a dose escalation study.
(10) The data shown in the present disclosure represent approximated, experimental values that can vary within a range of ±20%, preferably ±10%, and most preferably ±5%.
(11) The present invention provides a method for treating obesity, comprising: administering an effective amount of a polysaccharide sub-fraction isolated from H. sinensis to an obese subject. The experiments described below show the effects of the isolated polysaccharide sub-fraction on body weight and fat levels in mice fed a HFD. Generally, the polysaccharide extracted from H. sinensis in the present invention can be given to mammals and humans at a dose of 0.001-1,000 mg/kg of body weight per day. The details of the invention are given below.
Example 1
Preparation of H. sinensis Water Extracts and Polysaccharide Sub-Fractions
(12) In the present invention, a sub-fraction of H. sinensis polysaccharides is described that can effectively prevent and treat obesity and reduce fat accumulation in animals and humans. The H. sinensis polysaccharide sub-fraction of the present invention can be added to the diet of the subject as a drink, a daily supplement, or a food, without incurring in significant lifestyle changes, toxicity, or other unfavorable effects on the subject's health.
(13) 1.1 Preparation of Water Extracts of H. sinensis
(14) As shown in
(15) 1.2 Preparation of H. sinensis Crude Polysaccharide Extract
(16) Referring to
(17) 1.3 Fractionation of H. sinensis Crude Polysaccharide Extract
(18) 2,400 mL of H. sinensis crude polysaccharide extract is placed into a beaker and incubated at 50° C. in a water bath. The extract is fractionated using a TFF system (KrosFlo, Spectrum Laboratories) with a 0.2-μm hollow fiber membrane (1,500 cm.sup.2, polyethersulfone, PES). The trans-membrane pressure (TMP) is set at 15-16 psi. 600 mL of distilled water is added into the retentate during filtration when the volume of the retentate ranges from 800 to 1,000 mL. Addition of water is repeated two times (a total of 1,800 mL distilled water is added to the retentate). A 1,250 mL retentate (labeled as CS-1-1, total water-soluble polysaccharide of 0.24 g) and 3,600 mL of filtrate are obtained this way.
(19) The above-mentioned 3,600 mL of 0.2-μm filtrate is placed into a beaker and incubated at 50° C. in a water bath. The 3,600 mL of filtrate is fractionated using TFF with a 300-kDa cassette membrane (50 cm.sup.2, PES). The TMP is set between 18-20 psi. 600 mL of distilled water is added into the retentate during filtration when the volume of the retentate ranges from 1,000 mL to 1,200 mL. 1,040 mL of retentate (labeled as CS-1-2, total water-soluble polysaccharide of 0.18 g) and 3,600-mL of filtrate are obtained. Fractions CS-1-1 and CS-1-2 are combined to obtain a volume of 2,290 mL (labeled as sub-fraction CS-1, containing 0.42 g of total water-soluble polysaccharides; see Table 2).
(20) The above-mentioned 3,600 mL of 300-kDa filtrate is placed into a beaker and incubated at 50° C. in a water bath. The 300-kDa filtrate is fractionated using TFF with a 10-kDa cassette membrane (50 cm.sup.2, PES). The TMP is set between 18-20 psi. 600 mL of distilled water is added into the retentate during filtration when the volume of the retentate ranges from 1,000 mL to 1,200 mL. The operation is repeated to obtain 990 mL of 10-kDa-to-300 kDa retentate (labeled as sub-fraction CS-2, total water soluble-polysaccharides of 0.64 g; see Table 2) and 3,600 mL of 10 kDa filtrate (labeled as sub-fraction CS-3, total water-soluble polysaccharides of 0.16 g; see Table 2). The CS-1, CS-2, CS-3 and CS-4 sub-fractions are concentrated separately using the vacuum concentrator to obtain a final volume of 120 mL. Concentrated fractions are sterilized at high temperature and pressure in an autoclave for 20 min.
(21) 1.4 Determination of Total Water-Soluble Carbohydrates and Polysaccharides in Water Extracts and Polysaccharide Sub-Fractions Isolated from H. sinensis
(22) The phenol-sulfuric acid assay is used to determine the level of total water-soluble carbohydrates and polysaccharides in the extracts and sub-fractions isolated from H. sinensis, which comprise: 20% (w/v) the H. sinensis water extract (labeled as W1; 120 mL), the H. sinensis crude polysaccharide extract (labeled as W2; 2,400 mL), a combination of the retentate of the 0.2-μm filtration step and the 300-kDa-cutoff pore filtration (labeled as CS-1 sub-fraction; 2,290 mL), the retentate of the 10-kDa membrane filtration (labeled as CS-2 sub-fraction; 990 mL), the filtrate of the 10-kDa-cutoff membrane filtration (labeled as CS-3 sub-fraction; 3,600 mL), and the supernatants obtained after precipitation induced by addition of 95% ethanol (labeled as CS-4 sub-fraction; 1,040 mL). To establish a standard curve for the phenol-sulfuric acid assay, glucose standard solutions are prepared at concentrations of 0, 0.02, 0.04, 0.06, 0.08, 0.10, 0.12, 0.14, 0.16, 0.18, and 0.20 mg/mL. 200 μL of each solution is placed into 1.5-mL tubes. 200 μL of 5% phenol is added and the solution is mixed. 1 mL of sulfuric acid is added and the solution is mixed. After incubation for 20 min, absorbance at 490 nm is monitored using a spectrophotometer to obtain the calibration curve of standard glucose solutions (calculated R.sup.2>0.99). After appropriate dilution of the sample solutions, 200 μL of each diluted sample solution is placed into 1.5-mL tubes. Phenol and sulfuric acid are added as above and absorbance is measured. The values obtained are plotted onto the calibration curve to determine the concentration of total water-soluble carbohydrates or polysaccharide of the samples.
(23) Total water-soluble carbohydrates and polysaccharides found in the water extracts and polysaccharide sub-fractions isolated from H. sinensis are shown in Tables 1 and 2, which show that the W2 crude polysaccharide extract contains 0.42 g of water-soluble polysaccharides with a molecular weight above 300 kDa (CS-1), which accounts for 33.3% of total polysaccharides found in the W2 crude extract. The W2 crude polysaccharide extract also contains 0.64 g of polysaccharides with a molecular weight between 10 kDa and 300 kDa (CS-2), which accounts for 50.8% of the total polysaccharides found in the W2 crude polysaccharide extract. Finally, the W2 extract contains 0.16 g of carbohydrates with a molecular weight lower than 10 kDa (CS-3), which accounts for 12.7% of total carbohydrates found in the W2 extract.
(24) TABLE-US-00001 TABLE 1 Water-soluble carbohydrates and polysaccharides found in the extracts and sub-fractions isolated from H. sinensis Content Percentage Fraction (g) (%) W1 Total water-soluble carbohydrates 2.09 100 W2 Total water-soluble polysaccharides 1.26 60.3 CS-4 Mono-, di-, oligo-saccharides 0.83 39.7
(25) TABLE-US-00002 TABLE 2 Polysaccharide distribution of the crude H. sinensis polysaccharide extract (W2) Content Percentage Fraction (g) (%) W2 Total water-soluble carbohydrates 1.26 100 CS-1 MWCO > 300 kDa 0.42 33.3 CS-2 300 kDa > MWCO > 10 kDa 0.64 50.8 CS-3 10 kDa > MWCO 0.16 12.7 MWCO: molecular weight cut-off
1.5 Monosaccharide Analysis of CS-1 Polysaccharide Sub-Fraction Isolated from H. sinensis
(26) High pH anion exchange chromatography-pulsed amperometric detection (HPAEC-PAD) is used to analyze the monosaccharide composition of the CS-1 sub-fraction, which is selected here for further analysis. Monosaccharide standard solutions of L-fucose, L-rhamnose, D-galactosamine, D-arabinose, D-glucosamine, D-galactose, D-glucose and D-mannose are prepared at concentrations of 0.1, 0.5, 1, 2, and 5 mg/L. 25 μL of each solution is used for ionic chromatography analysis with the HPAEC-PAD Dionex ICS-5000 system (CarboPacPA1 column with an internal diameter of 4×250 mm, Thermo Scientific). Elution is performed with 16 mM NaOH (which corresponds to a mixture of water and 200 mM NaOH at a volume ratio of 92:8) and the flow rate is 1 mL/min. The temperature of the column is set at 30° C. After 30 min of analysis, peak area of each monosaccharide standard is determined at 0.1, 0.5, 1, 2, and 5 mg/L. The standard curve of monosaccharide standards is established (R.sup.2>0.99).
(27) 1 mL of CS-1 sub-fraction (3 mg of total water-soluble polysaccharides) is hydrolyzed with 1.79 mL of distilled water and 1.33 mL of trifluoroacetic acid at 112° C. in a sealed tube for 12 hours. The acid is removed by co-distillation with water after hydrolysis is completed. Each hydrolysate (1 mg) is dissolved in pure water (1 mg/mL). After a 4-fold dilution of the hydrolysate with pure water (0.25 mg/mL), 25 μL of the hydrolysate solution is used for ionic chromatography-HPAEC-PAD analysis. Elution is performed with 16 mM NaOH as described above. After 30 min of analysis, the analytic HPAEC-PAD profile of the hydrolysate solution is acquired. The monosaccharide composition and molar ratio of the CS-1 sub-fraction is determined by comparison with the standard curve. The CS-1 sub-fraction contains 3.2% fucose, 3.4% rhamnose, 1.7% arabinose, 4.6% glucosamine, 23.8% galactose, 12.5% glucose, 50.4% mannose, and 0.4% galactosamine (Tables 3 and 4 and
(28) TABLE-US-00003 TABLE 3 Monosaccharide composition of the CS-1 polysaccharide sub-fraction isolated from H. sinensis Percentage Monosaccharide (%) Fucose 3.2 Rhamnose 3.4 Arabinose 1.7 Glucosamine 4.6 Galactose 23.8 Glucose 12.5 Mannose 50.4 Galactosamine 0.4
(29) TABLE-US-00004 TABLE 4 Monosaccharide molar ratio of the CS-1 polysaccharide sub-fraction isolated from H. sinensis Monosaccharide Molar ratio Fucose 0.07 Rhamnose 0.07 Arabinose 0.04 Glucosamine 0.09 Galactose 0.47 Glucose 0.25 Mannose 1 Galactosamine 0.01
1.6 Molecular Weight Distribution of the CS-1 and CS-2 Polysaccharide Sub-Fractions Isolated from H. sinensis
(30) The molecular weight of the isolated CS-1 polysaccharide sub-fraction is analyzed using size-exclusion chromatography (SEC) and high performance liquid chromatography with a refractive index (RI) detector (model 2410, Waters) and light scattering (LS) detector (model 270 dual detector, Viscotek). Dextran 670 (667,800 Da) at 1.5 mg/mL is used as standard marker to calibrate the system. 100 μL of sample is analyzed on two connected GPC columns (TSKgel G5000PWxL and TSKgel G6000PWxL; 7.8×300 mm). Elution is performed with 0.02% NaNO.sub.3 in pure water and the flow rate is set at 0.5 mL/min (column temperature of 45° C.).
(31) The molecular weight of the CS-1 polysaccharide sub-fraction is analyzed using the OmniSEC software (Viscotek) and the following equations: Mn: number average molecular weight
(32)
(33)
(34)
(35) Analysis of the CS-1 sub-fraction (4 mg/mL of total water-soluble polysaccharides) using the GPC/SEC system and the RI and LS detectors is shown in
(36) The cumulative weight fraction values of the CS-1 sub-fraction at 0.95 (5%) and 0.05 (95%) correspond to molecular weights of 15,776 Da and 1,231,969 Da, respectively. The polysaccharide fraction between 15,776 Da and 1,231,969 Da represents approximately 90% of the total polysaccharide weight. The polydispersity index (Mw/Mn) is measured as 7.475. Table 5 shows a comparison of the molecular weight for the CS-1 and CS-2 polysaccharide sub-fractions.
(37) TABLE-US-00005 TABLE 5 Molecular weight comparison of the CS-1 and CS-2 sub-fractions Parameter CS-1 CS-2 Mn (Daltons) 41,731 38,842 Mw (Daltons) 311,921 49,215 Mz (Daltons) 7,589,000 79,949 Mw/Mn (Polydispersity index) 7.475 1.267 MW of 5% of cumulative WF (Daltons) 15,776 22,563 MW of 95% of cumulative WF (Daltons) 1,231,969 109,219 MW: molecular weight WF: weight fraction
Example 2
Effects of H. sinensis Polysaccharide Sub-Fractions on Body Weight and Fat Accumulation in HFD-Fed Mice
(38) C57BL/6NCrlBltw mice are fed with either standard chow (13.5% of energy from fat) as control group (Chow) or HFD (60% of energy from fat) as experimental group. The mice are also treated daily with 100 μL of polysaccharide sub-fraction (CS-1, CS-2, CS-3, or CS-4) or distilled water by intragastric gavage for three months (n=10 mice for each group). The mouse groups consist of the following: HFD+CS-1, HFD+CS-2, HFD+CS-3, HFD+CS-4, HFD, Chow+CS-1, Chow+CS-2, Chow+CS-3, Chow+CS-4, and Chow.
(39) As shown in
(40) Based on the results shown in
(41) The present invention provides a method for treating obesity by using H. sinensis polysaccharides and a method for preparing the H. sinensis polysaccharides having anti-obesity properties. The H. sinensis polysaccharides of the present invention can reduce body weight and fat accumulation in animals and humans. Accordingly, the present invention provides a new strategy to reduce obesity and induce weight loss in humans. The present invention has obvious potential commercial applications given the vast amount of products and treatments available to reduce body weight and maintain optimal health and well-being.
(42) Although the present invention has been described with reference to the preferred embodiments, it will be apparent to those skilled in the art that a variety of modifications and changes may be made without departing from the scope of the present invention which is intended to be defined by the appended claims.